Business
Novavax to deliver 60 mln doses of COVID-19 vaccine candidate to UK for trial – The Jakarta Post – Jakarta Post
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.
The trial will be a study in about 9,000 adults between 18 years and 85 years of age.
Novavax would partner…
-
Noosa News23 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News24 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
General21 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News18 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project